Drug · CHEMBL707
DOXAZOSIN
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. DOXAZOSIN. Drugs and targets, record CHEMBL707. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL707
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
Targets3
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| ADRA1A | Adrenergic receptor alpha-1 | Adrenergic receptor alpha-1 antagonist | ANTAGONIST | https://conductscience.org/library/genes/148 |
| ADRA1B | Adrenergic receptor alpha-1 | Adrenergic receptor alpha-1 antagonist | ANTAGONIST | https://conductscience.org/library/genes/147 |
| ADRA1D | Adrenergic receptor alpha-1 | Adrenergic receptor alpha-1 antagonist | ANTAGONIST | https://conductscience.org/library/genes/146 |
Source ChEMBL
Diseases22
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| hypertensive disorder | Approval | ATC and TTD | 12 | 10 | https://conductscience.org/library/drugs?q=MONDO_0005044 |
| post-traumatic stress disorder | Phase 2 | ClinicalTrials.gov | 4 | 4 | https://conductscience.org/library/drugs?q=MONDO_0005146 |
| alcohol dependence | Phase 2 | ClinicalTrials.gov | 3 | 3 | https://conductscience.org/library/drugs?q=MONDO_0007079 |
| benign prostatic hyperplasia | Phase 2 | ClinicalTrials.gov | 3 | 3 | https://conductscience.org/library/drugs?q=MONDO_0010811 |
| cocaine dependence | Phase 2 | ClinicalTrials.gov | 3 | 3 | https://conductscience.org/library/drugs?q=MONDO_0005186 |
| coronary artery disorder | Phase 3 | ClinicalTrials.gov | 2 | 2 | https://conductscience.org/library/drugs?q=MONDO_0005010 |
| myocardial infarction | Phase 3 | ClinicalTrials.gov | 2 | 2 | https://conductscience.org/library/drugs?q=MONDO_0005068 |
| Sleep disturbance | Phase 2 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=HP_0002360 |
| adrenal gland pheochromocytoma | Phase 3 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0004974 |
| angina pectoris | Unknown | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=EFO_0003913 |
1 to 10 of 22Source Open Targets
See all 22 diseasesTrials50
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT00535925 | Nephropathy In Type 2 Diabetes and Cardio-renal Events | Phase 4 | 850 | 2020-05-11 | doxazosin | Its name | ClinicalTrials.gov |
| NCT01661621 | Antimuscarinics as the First-line Treatment for Male With IPSS-V/S≤1 | Phase 4 | 395 | 2014-06-25 | doxazosin | Its name | ClinicalTrials.gov |
| NCT02500602 | CAP: Doxazosin in the Treatment of Co-Occurring PTSD and Alcohol Use Disorders | Phase 2 | 144 | 2021-04-14 | doxazosin | Its name | ClinicalTrials.gov |
| NCT01678313 | Cyclooxygenase-2 (COX-2) Inhibitor Reduces Serum Prostatic Specific Antigen (PSA) Levels | Phase 2 | 140 | 2014-06-30 | doxazosin | Its name | ClinicalTrials.gov |
| NCT00661895 | Black Education and Treatment of Hypertension (BEAT HTN) | Phase 4 | 99 | 2012-12-04 | doxazosin | Its name | ClinicalTrials.gov |
| NCT01145183 | Pharmacogenetics of Doxazosin for Cocaine Dependence | Phase 2 | 96 | 2019-07-22 | doxazosin | Its name | ClinicalTrials.gov |
| NCT02989493 | Testing Doxazosin to Treat Stress Mechanisms in Alcoholism | Phase 2 | 61 | 2021-03-18 | doxazosin | Its name | ClinicalTrials.gov |
| NCT01953432 | Pharmacogenetic Trial of Doxazosin for Treatment of Cocaine Abuse | Phase 2 | 43 | 2020-02-20 | doxazosin | Its name | ClinicalTrials.gov |
| NCT03176693 | Preoperative Alpha Blockade for Pheochromocytoma | Phase 3 | 39 | 2023-11-20 | doxazosin | Its name | ClinicalTrials.gov |
| NCT00880997 | The Efficacy of Doxazosin for Cocaine Users | Phase 1 | 35 | 2019-08-22 | doxazosin | Its name | ClinicalTrials.gov |
1 to 10 of 50
See all 50 trialsComparisons in its trials23
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Conventional Therapy vs Intensified Therapy: Number of Participants With Overall Fatal and Non-fatal, Major Adverse Cardiovascular Events (MACEs) | 146 of 188 | 116 of 207 | 395 | NCT00535925 | Trial comparisons |
| Conventional Therapy vs Intensified Therapy: deaths from any cause | 103 of 188 | 86 of 207 | 395 | NCT00535925 | Trial comparisons |
| Conventional Therapy vs Intensified Therapy: serious adverse events | 88 of 188 | 69 of 207 | 395 | NCT00535925 | Trial comparisons |
| Group 1 vs Group 2: serious adverse events | 0 of 116 | 0 of 279 | 395 | NCT01661621 | Trial comparisons |
| Multifactorial Intensified Therapy vs Standard of Care (SoC) Therapy: Number of Participants Who Achieved of BP, HbA1c and Total, HDL and LDL Cholesterol Goals at the End of Intervention Phase | 191 of 199 | 150 of 169 | 368 | NCT00535925 | Trial comparisons |
| Doxazosin vs Placebo: deaths from any cause | 0 of 74 | 0 of 70 | 144 | NCT02500602 | Trial comparisons |
| Doxazosin vs Placebo: serious adverse events | 12 of 74 | 9 of 70 | 144 | NCT02500602 | Trial comparisons |
| Study Group vs Control Group: serious adverse events | 0 of 64 | 0 of 58 | 122 | NCT01678313 | Trial comparisons |
| Intervention vs Control: serious adverse events | 0 of 49 | 0 of 50 | 99 | NCT00661895 | Trial comparisons |
| Doxazosin vs Placebo: deaths from any cause | 0 of 47 | 0 of 29 | 76 | NCT01145183 | Trial comparisons |
1 to 10 of 23
See all 23 comparisons in its trialsPapers from its trials96
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials4
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome | Source |
|---|---|---|---|
| Delay Discounting | 1 | 0 | ConductCognition |
| Emoji Emotion Recognition | 1 | 0 | ConductCognition |
| Food Cue Reactivity Task | 1 | 0 | ConductCognition |
| Social Value Orientation | 1 | 0 | ConductCognition |
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL707
GET https://conductscience.org/api/drugs/v1/CHEMBL707/diseases?page=2